Notice of allowance of patent received
Tissue Regenix receives notice of allowance of patent covering core orthopaedic development programme dCELL® Meniscus
YORK, 10 March, 2011 - Tissue Regenix, a regenerative medical device company focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability, announces that the European Patent Office (EPO) has issued the company a notice of allowance of a patent covering preparation of tissue for knee meniscus implantation using Tissue Regenix's proprietary dCELL® decellularisation technology.
The patent forms part of the exclusive worldwide license held by the company from the University of Leeds relating to its dCELL® Technology.
Antony Odell, Managing Director of Tissue Regenix, said: "We are very pleased with the notice of allowance of a patent protecting one of our core development programmes, dCELL® Meniscus for the repair of damaged knee meniscus, which will target the £2 billion global meniscus repair market."
ENDS
Enquiries:
|
Financial Dynamics Ben Atwell / John Dineen |
+44 (0) 20 7831 3113 |
|
|
|
|
Tissue Regenix Group plc Antony Odell |
+44 (0) 1904 567 609 |
|
|
|
|
Peel Hunt LLP (Nominated adviser) James Steel / Vijay Barathan |
+44 (0) 20 7418 8900 |
About Tissue Regenix
Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.
About dCELL® Technology
The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms.
Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).
This information is provided by RNS